Stakeholders welcome FDA’s framework for DHTs in drug development, cite challenges with adoption

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleResearch, Design and Development